Tag: Sgc stimulators

According to a 2023 meta-analysis, switching to riociguat from phosphodiesterase-5 (PDE5) inhibitors can significantly improve hemodynamics and exercise capacity in some pulmonary hypertension patients. While no direct generic equivalent exists, the question of **what drug is similar to riociguat** involves exploring other medications acting on the same or related pathways to address the condition.

While both riociguat (Adempas) and vericiguat (Verquvo) belong to the same class of soluble guanylate cyclase (sGC) stimulators, they are approved for distinctly different conditions. Choosing the 'better' drug is not a simple comparison, but rather an assessment of which medication is appropriate for a patient's specific diagnosis.